Helix BioPharma Corp. (TSX , FSE : ” HBP” ), a biopharmaceutical company
dedicated to developing drugs for prevention and treatment of cancer, today announced that it has
been advised by Dr. Marek Orlowski, a member of the board of directors of Helix and Chairman of
the Supervisory Board of Helix Polska, that he has purchased 1,000,000 previously issued and
outstanding shares of Helix for a total purchase price of approximately CAD$1.72 million since
December 30, 2013.
- 0 Comments
- FY2014